Geron CorpGERN
Price (close)
$1.26
Market cap
$809.5M
P/E
—
Revenue (TTM)
—
Net income
-$67.6M
Dividend yield
—
1-year total return
-0.8%
Net margin
—
Revenue growth
—
Debt / equity
0.55x
What Geron Corp does.
cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the
blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-
decreased quality of life. We believe that the results of our Phase 3 clinical trial, IMerge, in LR-MDS, favorable FDA label
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $253,000 | $1.4M | $596,000 | $237,000 | — | — |
| Net income | -$75.6M | -$116.1M | -$141.9M | -$184.1M | -$174.6M | -$83.5M |
| Free cash flow | -$67.1M | -$95.8M | -$127.8M | -$168.6M | -$219.3M | — |
More on GERN.
- Geron Corp summary
- Geron Corp financial statements
- Geron Corp key metrics
- Geron Corp health scores and style box
- Geron Corp earnings
- Geron Corp dividends
- Geron Corp valuation
- Geron Corp ownership and insiders
- Geron Corp peers
Figures from Geron Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.